Business Context and Reporting Period
Company: Atomera Inc (ATOM)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: Atomera is an early-stage semiconductor technology company developing and licensing proprietary processes, specifically Mears Silicon Technology (MST), to enhance transistor performance. The company does not manufacture chips but licenses technology to foundries, IDMs, and fabless manufacturers. It operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $11,000 | $22,000 | $15,000 | $112,000 |
| Cost of Revenue | ($128,000) | ($3,000) | ($190,000) | ($110,000) |
| Gross Loss | ($117,000) | $19,000 | ($175,000) | $2,000 |
| Operating Expenses | $5,676,000 | $4,819,000 | $16,336,000 | $14,466,000 |
| Net Loss | ($5,573,000) | ($4,595,000) | ($15,749,000) | ($13,778,000) |
| Net Loss Per Share (Basic/Diluted) | ($0.17) | ($0.17) | ($0.51) | ($0.52) |
| Cash and Cash Equivalents (End of Period) | Balance Sheet (Sep 30, 2025) Cash: $20.3M Working Capital: $18.1M Total Assets: $21.9M Total Liabilities: $2.9M |
|||
| Operating Cash Flow (YTD) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 50% in Q3 2025 compared to Q3 2024 ($11k vs. $22k) and 87% on a YTD basis ($15k vs. $112k). The decline is attributed to the mix of license and engineering services.
- Increased Operating Expenses: Total operating expenses rose 18% in Q3 and 13% YTD.
- R&D: Increased 20% in Q3 and 17% YTD, driven by higher outsourced engineering costs, payroll, and stock-based compensation.
- G&A: Increased 19% in Q3 and 16% YTD, primarily due to higher stock-based compensation and legal fees.
- Selling & Marketing: Decreased 17% in Q3 and 41% YTD due to headcount reductions.
- Cost of Revenue Volatility: Cost of revenue surged to $128k in Q3 2025 from $3k in Q3 2024, resulting in a negative gross margin, whereas the prior year showed a positive margin.
- Capital Raising: The company raised approximately $5.2 million in net proceeds during the first nine months of 2025 through At-The-Market (ATM) offerings and stock option exercises.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash reserves ($20.3 million) and working capital ($18.1 million) are sufficient to fund operations for at least the next 12 months. However, future capital needs depend on commercialization success.
- Financing Activities: The 2022 ATM facility expired in March 2025. A new 2025 ATM facility with Craig-Hallum was established in May 2025, allowing for up to $50 million in aggregate proceeds. Subsequent to the quarter end, the company raised an additional $836,000 via this facility.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to a previously identified material weakness regarding the review and approval of journal entries. While enhanced controls were implemented in 2025, management is still testing to confirm remediation.
- Risk Factors: Primary risks include the inability to generate sufficient revenue from licensing to meet cash needs, potential need for additional capital dilution, and the inherent risks of an early-stage technology company with recurring losses.
Investor Verification Checklist
- Runway Validation: Verify the 12-month liquidity projection against current burn rates, noting the significant increase in R&D and G&A expenses.
- Revenue Sustainability: Investigate the cause of the sharp revenue decline (87% YTD) and the shift from positive to negative gross margins.
- Internal Control Remediation: Monitor future filings for confirmation that the material weakness in journal entry controls has been fully remediated and tested.
- ATM Utilization: Track the utilization of the new 2025 ATM facility and the impact of share issuance on dilution (31.7M shares outstanding as of Oct 23, 2025).
- Lease Obligations: Review the specific terms of the epitaxial deposition tool leases, which represent a significant portion of financing lease liabilities and operating costs.